Medi-Caps Q4 FY26 Results: PAT Rs 3.04 Cr

Medi-Caps Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 3.04 crore for the quarter ended March 31, 2026, up 76.7% YoY compared to Rs 1.72 crore in Q4 FY25. Revenue from operations stood at Rs 3.45 crore. Results are on a Consolidated basis. Medi-Caps is a Pharmaceutical Capsules company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Medi-Caps Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	3.45	N/A	N/A
Net Profit	3.04	1.72	+76.7%
Basis	Consolidated

Note: Medi-Caps Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Medi-Caps Q4 FY26 Performance Analysis

The Medi-Caps Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. Strong PAT growth of 76.7% YoY to Rs 3.04 crore demonstrates significant earnings improvement. Medi-Caps operates in the Pharmaceutical Capsules sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue of Rs 3.45 crore reflects steady business conditions in the Pharmaceutical Capsules sector.

Screen the best stocks on the Univest Screener.

Key Factors Driving Medi-Caps Q4 FY26 Results

Revenue and Business Performance

The revenue of Rs 3.45 crore was for the quarter ended March 31, 2026. Revenue momentum reflects steady demand in the Pharmaceutical Capsules business.

Profitability and Margins

The business PAT of Rs 3.04 crore is up 76.7% YoY. The strong PAT growth demonstrates improving operational leverage and cost discipline.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharmaceutical Capsules sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharmaceutical Capsules sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.